Despite its prevalence and (. Some would argue) popularity throughout the country, Pennsylvania doctors are not required to participate in collaborative drug management with pharmacists; It is completely voluntary. However, if they choose to do so, there are a few rules to follow. (It wouldn`t be a regulatory blog if I didn`t talk about rules, would it? That`s right.) (c)] (d) The written record shall be filed with the Bureau. [d] (e) The written protocol shall be valid for a maximum period of two years from the date of execution. At the end of the two-year period or earlier, the parties shall review the written record and make a decision regarding its extension, necessary amendments or terminations. (c) A pharmacist may not offer a doctor economic or other incentives, incentives or benefits to conclude a cooperation agreement for the management of drug therapy. (ii) The term excludes medication management services in pharmacy practice which, pursuant to the Medicare Prescription, Improvement, and Modernization Act of 2003 (Pub). L.
No. 108-173, 117 Stat. 2066) [(b)] (c) The written minutes should be available as follows: the Commission proposes to amend paragraph 27.1 by amending the definition of „the practice of pharmacy“ to comply with the definition in the Act. Amendments to the 2010 Act changed the term „drug therapy management“ to „drug therapy management“. The board`s rules do not define „drug therapy management.“ Instead, Article 27(1) defines the term `management of drug therapy`. The Board of Directors proposes to use the legal concept of „drug therapy management“, as defined in the law, throughout the proposed regulations.